Neuroscientific Biopharmaceuticals Ltd has released a press release.
CEO Resignation
Filed with ASX ·
On 6ix: 6ix.com/news/ceo-resignation-5
6ix hasn’t read this filing yet.
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- HREC decision to not approve Phase I Clinical Trial
- 2022 Annual Report and Appendix 4E
- NeuroScientific releases FY2022 Results
- HREC Submission for Phase I Clinical Trial
- First Subject Recruited for Early-Phase Clinical Trial
Later from Neuroscientific Biopharmaceuticals
- Investor Update Presentation
- Appointment of Interim CEO
- NSB files new patent
- R&D Tax Incentive Refund Received
- Positive treatment effect in MS animal study
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals